Alterity Therapeutics logo
Alterity Therapeutics
ATHE | NASDAQ
Chart Builder DCF Calculator
$1.96
$0.00 (0.00%)
At close: Nov 16, 2026, 4:00 PM ET
$1.96
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

Alterity Therapeutics Company Profile

Company profile explained

Company Profile

Alterity Therapeutics Limited, an Australian biopharmaceutical firm, focuses on the discovery and development of novel drug treatments for various neurological disorders, such as Alzheimer's, Huntington's, and Parkinson's diseases. Its prominent experimental therapy, ATH434, has completed Phase I clinical trials targeting Parkinson's disease. The company is also advancing PBT2, a compound that has successfully undergone Phase IIa clinical testing for Alzheimer's disease. Established in 1997, the entity was formerly known as Prana Biotechnology Limited before rebranding to Alterity Therapeutics Limited in April 2019, and its main operations are based in Melbourne, Australia.

Key Executives

Name Position
David A. Stamler CEO, MD & Director
Abby Macnish Niven Chief Financial Officer & Company Secretary
Robert Cherny Head of Research
Rudolph Emile Tanzi Chief Scientific Advisor and Member of Research & Development Advisory Board
Steven D. Targum Chief Medical Advisor

Latest SEC Filings

Date Type Title
Oct 30, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 23, 2026 6-K Filing
Oct 21, 2026 6-K Filing
Oct 21, 2026 6-K Filing
Oct 19, 2026 6-K Filing
Oct 09, 2026 6-K Filing
Oct 05, 2026 6-K Filing
Sep 25, 2026 6-K Filing
View All SEC Filings ➞
Alterity Therapeutics
Alterity Therapeutics logo
Country Australia
IPO Date Sep 29, 2003
Industry Biotechnology
Sector Healthcare
Employees 11
CEO David A. Stamler

Contact Details

500 Collins Street Melbourne, VIC 3000 Australia

Stock Details

Ticker Symbol ATHE
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001131343
CUSIP Number 02155X205
ISIN Number US02155X2053
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.